State Street Corp Sells 1,805,779 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

State Street Corp reduced its position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 59.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,246,613 shares of the company’s stock after selling 1,805,779 shares during the quarter. State Street Corp owned approximately 1.75% of Zentalis Pharmaceuticals worth $4,588,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Erste Asset Management GmbH bought a new position in shares of Zentalis Pharmaceuticals during the 3rd quarter worth about $37,000. Paloma Partners Management Co acquired a new position in Zentalis Pharmaceuticals in the third quarter worth about $37,000. Aigen Investment Management LP acquired a new position in Zentalis Pharmaceuticals in the third quarter worth about $41,000. Capstone Investment Advisors LLC bought a new position in Zentalis Pharmaceuticals during the third quarter worth about $48,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Zentalis Pharmaceuticals by 63.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock valued at $50,000 after purchasing an additional 5,333 shares in the last quarter.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL stock opened at $3.06 on Monday. Zentalis Pharmaceuticals, Inc. has a 52 week low of $2.66 and a 52 week high of $18.07. The stock has a market capitalization of $218.07 million, a PE ratio of -1.23 and a beta of 1.84. The stock’s fifty day moving average is $3.34 and its 200-day moving average is $3.68.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.36. As a group, analysts forecast that Zentalis Pharmaceuticals, Inc. will post -2.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

ZNTL has been the subject of a number of recent research reports. Oppenheimer reissued an “outperform” rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a report on Monday, September 16th. Guggenheim dropped their price objective on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Finally, HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Zentalis Pharmaceuticals in a report on Friday, November 15th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $10.00.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.